Phase 3 N=360 Randomized Single-blind Treatment

Comparing Tissue Adhesives in Port Site Closure

Dermatitis, Contact

Bottom Line

View on ClinicalTrials.gov: NCT05492721 ↗

Enrolled (actual)

360

Serious AEs

0.0%

Results posted

May 2026

Primary outcome: Primary: Number of Participants Who Develop Contact Dermatitis — 21; 18 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Dermabond (2-Octylcyanoacrylate) (Device); Swiftset (N-butyl-2-cyanoacrylate) (Device); Liquiband (2-Octylcyanoacrylate) (Device)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: The University of Texas Health Science Center, Houston
Primary completion: Jun 2025

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Who Develop Contact Dermatitis	21; 18	—
SECONDARY Mean Diameter of Erythema	—	—
SECONDARY Number of Participants With Wound Dehiscence	0; 0	—
SECONDARY Number of Participants With Surgical Site Infection	0; 0	—

Summary

This is a multi-center randomized controlled trial to evaluate two different methods of reinforcing surgical port site closure: 2-Octylcyanoacrylate and n-butyl-2-cyanoacrylate.

Eligibility Criteria

Inclusion Criteria

18 or older
undergoing an elective laparoscopic or robotic abdominal surgery

Exclusion Criteria

Patients unlikely to follow-up (live out of state, unable to be reached by phone or email)
Patients with a known allergy to 2-Octylcyanoacrylate or N-butyl-2-cyanoacrylate.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05492721). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.